Latest Breaking News On - Biohaven labs - Page 3 : comparemela.com
Biohaven s BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19
primepublishers.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from primepublishers.com Daily Mail and Mail on Sunday newspapers.
Published: Jan 07, 2021
NEW HAVEN, Conn., Jan. 7, 2021 /PRNewswire/ Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the Company or Biohaven ) today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. ( Kleo ) that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab. In connection with these two transactions, Biohaven assumed Kleo s laboratory facilities located in Science Park in New Haven, Connecticut and formed Biohaven Labs to serve as the integrated chemistry and discovery research arm of Biohaven. Biohaven Labs will continue several existing Kleo discovery partnerships, including with the Bill and Melinda Gates Foundation for the development of a Hyperimmune Globulin Mimic (HGM) for COVID-19 and PeptiDream for the development of immuno-oncology therapeutics.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the
acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab. In connection with these two transactions, Biohaven assumed Kleo s laboratory facilities located in Science Park in New Haven, Connecticut and formed Biohaven Labs to serve as the integrated chemistry and discovery research arm of Biohaven. Biohaven Labs will continue several existing Kleo discovery partnerships, including with the Bill and Melinda Gates Foundation for the development of a Hyperimmune Globulin Mimic (HGM) for COVID-19 and PeptiDream for the development of immuno-oncology therapeutics.
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
- Acquires full ownership of Kleo Pharmaceuticals with two novel immune modulating platforms: the Multi-targeted Antibody Therapy Enhancer (MATE™) conjugation platform and Antibody Recruiting Molecule (ARM™) platform
- Enters into exclusive license agreement with Yale University for the development and commercialization of Yale s extracellular target degrader platform based on intellectual property derived from ground-breaking research in the laboratory of Professor David Spiegel
- Establishes Biohaven Labs at Science Park in New Haven to advance these three novel discovery platforms and several existing discovery partnerships to serve as an integrated chemistry and discovery research engine to complement Biohaven s late-stage clinical development and commercial expertise
vimarsana © 2020. All Rights Reserved.